These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32330187)

  • 1. Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma.
    Tagawa M; Tambo N; Maezawa M; Tomihari M; Watanabe KI; Inokuma H; Miyahara K
    PLoS One; 2020; 15(4):e0232365. PubMed ID: 32330187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF
    Maeda S; Yoshitake R; Chambers JK; Uchida K; Eto S; Ikeda N; Nakagawa T; Nishimura R; Goto-Koshino Y; Yonezawa T; Momoi Y
    Vet Pathol; 2021 Sep; 58(5):971-980. PubMed ID: 33205710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic value of the BRAF variant V595E in urine samples, smears and biopsies from canine transitional cell carcinoma].
    Aupperle-Lellbach H; Grassinger J; Hohloch C; Kehl A; Pantke P
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2018 Oct; 46(5):289-295. PubMed ID: 30541168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib).
    Kim JH; Ahn DH; Moon JS; Han HJ; Bae K; Yoon KA
    Vet Q; 2021 Dec; 41(1):153-162. PubMed ID: 33764261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target.
    Jung H; Bae K; Lee JY; Kim JH; Han HJ; Yoon HY; Yoon KA
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective detection of BRAF
    Aeschlimann L; Kehl A; Guscetti F; Posthaus C; Aupperle-Lellbach H; Rottenberg S; de Brot S
    Vet Comp Oncol; 2024 Jun; 22(2):295-302. PubMed ID: 38659202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and characterization of urothelial carcinoma cell lines with and without BRAF mutation (V595E) in dogs.
    Yamasaki H; Uematsu Y; Okano K; Ichikawa M; Tei M; Hirabayashi M; Uchida K; Ono K; Hirao H
    In Vitro Cell Dev Biol Anim; 2022 Dec; 58(10):898-911. PubMed ID: 36477686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of the BRAF
    Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
    Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coincidence of v-raf murine sarcoma viral oncogene homolog B mutation (V595E) with phosphorylated v-raf murine sarcoma viral oncogene homolog B in urothelial carcinoma in dogs.
    Yamasaki H; Uematsu Y; Hayashi Y; Yamashita M; Tei M; Uchida K; Ono K; Hirao H
    Can J Vet Res; 2022 Oct; 86(4):286-293. PubMed ID: 36211215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma.
    Mochizuki H; Breen M
    Vet Comp Oncol; 2017 Dec; 15(4):1598-1605. PubMed ID: 27714944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF mutation status and its prognostic significance in 79 canine urothelial carcinomas: A retrospective study (2006-2019).
    Gedon J; Kehl A; Aupperle-Lellbach H; von Bomhard W; Schmidt JM
    Vet Comp Oncol; 2022 Jun; 20(2):449-457. PubMed ID: 34878687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.
    Thomas R; Wiley CA; Droste EL; Robertson J; Inman BA; Breen M
    PLoS Genet; 2023 Apr; 19(4):e1010575. PubMed ID: 37079639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of BRAF Mutation in Urine DNA as a Molecular Diagnostic for Canine Urothelial and Prostatic Carcinoma.
    Mochizuki H; Shapiro SG; Breen M
    PLoS One; 2015; 10(12):e0144170. PubMed ID: 26649430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant expression of the COX2/PGE
    Yoshitake R; Saeki K; Eto S; Shinada M; Nakano R; Sugiya H; Endo Y; Fujita N; Nishimura R; Nakagawa T
    Sci Rep; 2020 May; 10(1):7826. PubMed ID: 32385388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. USE OF CIRCULATING TUMOR DNA FOR DETECTION OF BRAF V600E MUTATION AND TREATMENT MONITORING IN MELANOMA PATIENTS.
    Shapochka D; Shapochka T; Seleznyov O; Matveeva A; Dudin V
    Georgian Med News; 2018 Mar; (276):76-81. PubMed ID: 29697386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.
    Reid AL; Freeman JB; Millward M; Ziman M; Gray ES
    Clin Biochem; 2015 Oct; 48(15):999-1002. PubMed ID: 25523300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients.
    Pinzani P; Salvianti F; Cascella R; Massi D; De Giorgi V; Pazzagli M; Orlando C
    Clin Chim Acta; 2010 Sep; 411(17-18):1319-24. PubMed ID: 20576522
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Sakai K; Maeda S; Saeki K; Yoshitake R; Goto-Koshino Y; Nakagawa T; Nishimura R; Yonezawa T; Matsuki N
    Vet Pathol; 2020 Jan; 57(1):56-65. PubMed ID: 31640537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.
    Garlan F; Blanchet B; Kramkimel N; Puszkiel A; Golmard JL; Noe G; Dupin N; Laurent-Puig P; Vidal M; Taly V; Thomas-Schoemann A
    Target Oncol; 2017 Jun; 12(3):365-371. PubMed ID: 28527094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.